cofepris glp-1 news 🚀Could monthly be the next major advance in obesity treatment? By Pfizer 🚨Pfizer's Phase 2b VESPER-3 trial evaluating the ultra-long-acting GLP-1 receptor agonist PF-08653944. 🔺Designed… | Ahmad Bahareth, MD GLP-1 Receptor Agonists and vision

Purpose Glucagon-like receptor agonists (GLP1-RAs) have raised peri-procedural concerns due to their potential to delay gastric emptying

In this issue of Diabetologia, Maida et al

This article delves into key considerations and challenges health insurers face.

Nausea is a common side effect of weight-loss medication that can make it hard to go about your day

Nevertheless, bone consequences of intentional weight loss interventions in PwO are well known: (i) significant weight loss induced by caloric restriction and bariatric surgery results in accelerated bone turnover and bone loss, and (ii) unlike caloric restriction interventions, PwO experience a substantial deterioration in bone microarchitecture and strength associated with an increased risk of fracture after bariatric surgery especially malabsorptive procedures

Learn why it happens and discover Strive's Digest, a science-backed supplement for gentle, effective relief